Frequency Therapeutics Announces Positive Phase 1/2 Trial Results for Hearing Restoration Drug
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical…
Read More
Frequency Therapeutics Completes $42 Million Series B Financing
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced earlier this month that it has closed $42 million in Series B financing. The latest funding round for the company, which is seeking to create a new class of drugs based on small molecule stimulation of dormant stem cells within the body, brings the total capital raised…
Read MoreFrequency Therapeutics Completes Enrollment in Safety Trial for Hearing Restoration Drug Candidate, FX-322
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced this week the completion of enrollment in the single dose safety trial to evaluate FX-322, the company’s leading drug candidate for hearing restoration. The randomized, double-blind, placebo-controlled trial will be assessing the safety of a single dose of FX-322 given by intratympanic administration in adult patients with…
Read More
Frequency Therapeutics Launches US Clinical Trials of Hearing Loss Drug; Akouos Raises $50M for Gene Therapy R&D
Biotech startup, Frequency Therapeutics, announced today that the first patients have been treated in a Phase 1/2 clinical trial to evaluate the company’s investigative compound FX-322, the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration. The randomized, double-blind, placebo-controlled trial will assess the safety of FX-322 given by intratympanic administration in adult patients…
Read More
Frequency Therapeutics Receives $2M Grant to Investigate Hearing Restoration for US Military
Biotech startup, Frequency Therapeutics, announced today that it has received a U.S. Department of Defense (DoD) Hearing and Balance Research Award grant. The $2 million dollar, peer-reviewed grant will be used to investigate the company’s unique Progenitor Cell Activation (PCA) approach to hearing restoration for military personnel with service-related hearing loss. Prevention of hearing loss…
Read More
Frequency Therapeutics Announces Successful Completion of First-in-Human Study of FX-322, Company’s Leading Candidate for Hearing Restoration
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced late last month the successful completion of a first-in-human study of the company’s investigative compound FX-322, the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration. The preliminary results were recently presented at a lecture last month at the US-Japan Symposium on Drug Delivery. According to…
Read More
Hearing Restoration, PSAPs Among Hot Topics at JAMA
This year, 2017, marks the peak number of baby-boomers reaching the age of 60. So it’s no coincidence that researchers and public health officials have turned their attention to the plethora of chronic conditions, including hearing loss, that are linked to aging. The Journal of the American Medical Association, one of the most widely circulated…
Read MoreBiotech Startup, Frequency Therapeutics, Nets $32 Million Investment
WOBURN, MASSACHUSSETTS — Frequency Therapeutics, a biotech firm developing drugs to re-create sensory cells in the inner ear, announced that it had closed a $32 million Series A investment, led by CoBro Ventures. Other investors include Morningside Ventures, Emigrant Capital and Alexandria Real Estate Equities. Founded in 2015, Frequency’s approach is based on discoveries of…
Read More